292615-41-9 Usage
Uses
1. Used in Pharmaceutical Industry:
N,N’-Bis(2-mercaptobenzoyl)hydrazide is used as a selective inhibitor for HIV-1 integrase, which plays a crucial role in the replication of the virus. Its specificity for integrase means it does not affect other retroviral targets such as reverse transcriptase, protease, and virus attachment. Additionally, it does not exhibit detectable activity against human topoisomerases I and II at concentrations that effectively inhibit integrase, making it a potentially valuable compound in the development of antiretroviral therapies.
2. Used in Research and Development:
Due to its unique properties as a selective inhibitor, N,N’-Bis(2-mercaptobenzoyl)hydrazide can be utilized in research and development for studying the mechanisms of HIV-1 integrase and its role in the viral life cycle. N,N’-Bis(2-mercaptobenzoyl)hydrazide can also be used to develop new drugs or improve existing ones targeting this specific enzyme, potentially leading to more effective treatments for HIV.
3. Used in Drug Design and Screening:
N,N’-Bis(2-mercaptobenzoyl)hydrazide can be employed in drug design and screening processes to identify potential lead compounds with similar inhibitory properties against HIV-1 integrase. Its structural features can serve as a starting point for the development of new antiviral agents, contributing to the ongoing efforts to combat HIV and AIDS.
Check Digit Verification of cas no
The CAS Registry Mumber 292615-41-9 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 2,9,2,6,1 and 5 respectively; the second part has 2 digits, 4 and 1 respectively.
Calculate Digit Verification of CAS Registry Number 292615-41:
(8*2)+(7*9)+(6*2)+(5*6)+(4*1)+(3*5)+(2*4)+(1*1)=149
149 % 10 = 9
So 292615-41-9 is a valid CAS Registry Number.
292615-41-9Relevant academic research and scientific papers
Neamati, Nouri,Lin, Zhaiwei,Karki, Rajeshri G.,Orr, Ann,Cowansage, Kiriana,Strumberg, Dirk,Pais, Godwin C. G.,Voigt, Johannes H.,Nicklaus, Marc C.,Winslow, Heather E.,Zhao, He,Turpin, Jim A.,Yi, Jizu,Skalka, Anna Marie,Burke Jr., Terrence R.,Pommier, Yves
, p. 5661 - 5670 (2002)
Human immunodeficiency virus type 1 integrase (HIV-1 IN) is an essential enzyme for effective viral replication. Therefore, IN inhibitors are being sought for chemotherapy against AIDS. We had previously identified a series of salicylhydrazides as potent inhibitors of IN in vitro (Neamati, N.; et al. J. Med. Chem. 1998, 41, 3202-3209.). Herein, we report the design, synthesis, and antiviral activity of three novel mercaptosalicylhydrazide (MSH) derivatives. MSHs were effective against the IN catalytic core domain and inhibited IN binding to HIV LTR DNA. They also inhibited catalytic activities of IN in IN-DNA preassembled complexes. Site-directed mutagenesis and molecular modeling studies suggest that MSHs bind to cysteine 65 and chelate Mg2+ at the active site of HIV-1 IN. Contrary to salicylhydrazides, the MSHs are 300-fold less cytotoxic and exhibit antiviral activity. They are also active in Mg2+-based assays, while IN inhibition by salicylhydrazides is strictly Mn2+-dependent. Additionally, in target and cell-based assays, the MSHs have no detectable effect on other retroviral targets, including reverse transcriptase, protease, and virus attachment, and exhibit no detectable activity against human topoisomerases I and II at concentrations that effectively inhibit IN. These data suggest that MSHs are selective inhibitors of HIV-1 IN and may serve as leads for antiviral therapeutics.
